23094-96-4

Usage

Uses

Used in Organic Synthesis:
3-Bromo-4-methoxy-benzenesulfonyl chloride is used as an intermediate in organic synthesis for [application reason]. Its unique structure with bromine, methoxy, and sulfonyl chloride substituents makes it a valuable compound in the synthesis of various organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-Bromo-4-methoxy-benzenesulfonyl chloride is used as a building block for the development of new drugs. Its chemical properties allow it to be incorporated into the molecular structures of potential therapeutic agents, contributing to the discovery of novel medications.
Used in Chemical Research:
3-Bromo-4-methoxy-benzenesulfonyl chloride is also used in chemical research as a model compound to study the effects of different substituents on the reactivity and stability of benzene derivatives. This helps researchers understand the fundamental principles of organic chemistry and develop new synthetic strategies.

InChI:InChI=1/C7H6BrClO3S/c1-12-7-3-2-5(4-6(7)8)13(9,10)11/h2-4H,1H3

Upstream product

• 578-57-4 2-bromoanisole 

Downstream Products

• 170288-10-5 3-Bromo-4-methoxy-N-phenyl-benzenesulfonamide 
• 358665-60-8 3-bromo-N-tert-butyl-4-methoxy-benzenesulfonamide 
• 358665-70-0 3-bromo-4-methoxy-N,N-dimethylbenzenesulfonamide 
• 358665-54-0 3-bromo-4-methoxy-N-methylbenzenesulfonamide 
• 20951-42-2 2-bromo-4-methanesulfonyl-1-methoxy-benzene 
• 443296-06-8 C₁₄H₁₃BrClNO₃S 
• 1073265-07-2 N₁-(3-chloro-2-methylphenyl)-4-hydroxy-N₃-phenylbenzene-1,3-disulfonamide 
• 1073265-91-4 C₁₉H₂₃ClN₂O₅S 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: -CH2-, - CH2-CH2-, -CH2-CH2-CH2-, or -CH2-O-CH2-; and Z represents a hydrogen atom or a hydroxyl group.]

NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

A compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof: [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, or —CH2—O—CH2—; and Z represents a hydrogen atom or a hydroxyl group.]

N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS

The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as cancer, or diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER

A compound of formula (I), useful for the treatment of cancer, inflammation and inflammatory disorders, and a pharmaceutical composition containing the compound.

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

2-'5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl) methyl]-1H-pyrroles with high affinity and selectivity for the dopamine D3 receptor

A series of 2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl)methyl]-1H-pyrroles (8 - 15) has been prepared to investigate the effect on affinity and selectivity for the dopamine D3 receptor of modifying the substituent in the phenyl ring at the 2-position of the pyrrole. Sulfonate 7 and sulfonamides 12, 14, 15 were shown to have high affinities (pKi's 8.0 - 8.7) and selectivities (100 - 150-fold) for the D3 over the D2 receptor.